New advances in the treatment of gout: review of pegloticase

References

• SinghHTorralbaKDTherapeutic challenges in the management of gout in the elderlyGeriatrics200863713182018593209
   PubMed Web of Science ®Google Scholar
• PascualESiveraFWhy is gout so poorly managed?Ann Rheum Dis200766101269127017881662
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMPascualEfor EULAR Standing Committee for International Clinical Studies Including TherapeuticsEULAR evidence based recommendations for gout – Part I diagnosis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)Ann Rheum Dis200665101301131116707533
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMBardinTfor EULAR Standing Committee for International Clinical Studies Including TherapeuticsEULAR evidence based recommendations for gout – Part II management: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)Ann Rheum Dis200665101312132416707532
   PubMed Web of Science ®Google Scholar
• JordanKMCameronJSSnaithMfor British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG)British society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of goutRheumatology (Oxford)20084681372137417522099
   PubMed Web of Science ®Google Scholar
• ReindersMKJansenTLManagement of hyperuricemia in gout: focus on febuxostatClin Interv Aging2010571820169038
   PubMed Web of Science ®Google Scholar
• JansenTLRichettePPerez-RuizFInternational position paper on febuxostatClin Rheumatol201029883584020401506
   PubMed Web of Science ®Google Scholar
• MinerJNOstertagTHyndmanDRDEA684, a novel, potent and efficacious inhibitor of human urate transporter, URAT1, with a favorable pharmacokinetic profile, and no mitochondrial toxicityAnn Rheum Dis201069Suppl 3S122
   Google Scholar
• ShermanMRSaiferMGPerez-RuizFPEG-uricase in the management of treatment-resistant gout and hyperuricemiaAdv Drug Deliv Rev2008601596817826865
   PubMed Web of Science ®Google Scholar
• SavientSavient Announces KRYSTEXXA(TM) Resubmitted BLA Accepted for Review by the FDA Available from: http://investor.savient.com/ReleaseDetail.cfm?ReleaseID=455353Accessed 2010 Jul 7
   Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anesthesia, Analgesia, and Rheumatology ProductsAAC Briefing Document Krystexxa (Pegloticase)2009616 Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM165714.pdfAccessed 2010 Jul 7
   Google Scholar
• SavientSavient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) Available from: http://investor.savient.com/releasedetail.cfm?ReleaseID=400470Accessed 2010 Aug 7
   Google Scholar
• FerrazMBO’BrienBA cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritisJ Rheumatol19952259089148587081
   PubMed Web of Science ®Google Scholar
• SarawateCAPatelPASchumacherHRSerum urate levels and gout flares: analysis from managed care dataJ Clin Rheumatol2006122616516601538
   PubMed Web of Science ®Google Scholar
• ShojiAYamanakaHKamataniNA retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with anti-hyperuricemic therapyArthritis Rheum200451332132515188314
   PubMed Web of Science ®Google Scholar
• Li-YuJClayburneGSieckMTreatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?J Rheumatol200128357758011296962
   PubMed Web of Science ®Google Scholar
• Pérez-RuizFCalabozoMPijoanJIHerrero-BeitesAMRuibalAEffect of urate-lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Rheum200247435636012209479
   PubMed Web of Science ®Google Scholar
• Pérez-RuizFAlonso-RuizACalabozoMHerrero-BeitesAGarcía-ErauskinGRuiz-LuceaEEfficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic goutAnn Rheum Dis19985795455499849314
   PubMed Web of Science ®Google Scholar
• YamanakaHTogashiRHakodaMOptimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatmentAdv Exp Med Biol199843113189598023
   PubMed Web of Science ®Google Scholar
• JansenTLReindersMKvan RoonENBrouwersJRBJBenzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence?”Clin Exp Rheumatol200422565115485024
   PubMed Web of Science ®Google Scholar
• LeeMHGrahamGGWilliamsKMDayROA benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Drug Saf200831864366518636784
   PubMed Web of Science ®Google Scholar
• SutariaSKatbamnaRUnderwoodMEffectiveness of interventions for the treatment of acute and prevention of recurrent gout – a systematic reviewRheumatology (Oxford)200645111422143116632483
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENHoutmanPMBrouwersJRJansenTLBiochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patientsClin Rheumatol20072651459146517308859
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENJansenTLThAEfficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolAnn Rheum Dis2009681515618250112
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCJansenTLTAA randomized controlled trial with dose escalation on the efficacy and tolerability of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in gout patientsAnn Rheum Dis200968689289718633127
   PubMed Web of Science ®Google Scholar
• DalbethNKumarSStampLGowPDose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with goutJ Rheumatol20063381646165016783857
   PubMed Web of Science ®Google Scholar
• ChungYStockerSLGrahamGGDayROOptimizing therapy with allopurinol: factors limiting hypouricemic efficacyAm J Med Sci2008335321922618344696
   PubMed Web of Science ®Google Scholar
• PanomvanaDSripraditSAngthararakSHigher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney diseaseJ Clin Rheumatol200814161118431090
   PubMed Web of Science ®Google Scholar
• MockenhauptMViboudCDunantAStevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-studyJ Invest Dermatol20081281354417805350
   PubMed Web of Science ®Google Scholar
• BorstadGCBryantLRAbelMPScroggieDAHarrisMDAllowayJAColchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritisJ Rheumatol200431122429243215570646
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRBenjaminKLQuality of life and disability in patients with treatment-failure goutJ Rheumatol20093651041104819332629
   PubMed Web of Science ®Google Scholar
• VogtBUrate oxidase (rasburicase) for treatment of severe tophaceous goutNephrol Dial Transplant200520243143315673692
   PubMed Web of Science ®Google Scholar
• MoolenburghJDReindersMKJansenTLRasburicase treatment in severe tophaceous gout: a novel therapeutic optionClin Rheumatol200625574975216247589
   PubMed Web of Science ®Google Scholar
• RichettePBardinTSuccessful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinolNat Clin Pract Rheumatol20062633834216932713
   PubMedGoogle Scholar
• HaerlePSchlottermannKEhrensteinBPA patient with arthritis, severe back pain, impaired wound healing, and a perforated sigmoid colonLancet20063679527203216782495
   PubMed Web of Science ®Google Scholar
• SoAde SmedtTRevazSA pilot study of IL-1 inhibition by anakinra in acute goutArthr Res Ther200792R2817352828
   PubMed Web of Science ®Google Scholar
• RichettePBrièreCHoenen-ClavertVRasburicase for tophaceous gout not treatable with allopurinol: an exploratory studyJ Rheumatol200734102093209817896799
   PubMed Web of Science ®Google Scholar
• CammalleriLMalaguarneraMRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutInt J Med Sci200742839317396159
   PubMedGoogle Scholar
• TerkeltaubRLearning how and when to employ uricase as bridge therapy in refractory goutJ Rheumatol200734101955195817924606
   PubMed Web of Science ®Google Scholar
• DavisSParkYKAbuchowskiADavisFFHypouricaemic effect of polyethyleneglycol modified urate oxidaseLancet1981282412812836114326
   PubMed Web of Science ®Google Scholar
• BiggersKScheinfeldNPegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of goutCurr Opin Investig Drugs200894422429
   PubMedGoogle Scholar
• GansonNJKellySJScarlettESundyJSHershfieldMSControl of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseArthritis Res Ther200681R1216356199
   PubMed Web of Science ®Google Scholar
• SundyJSGansonNJKellySJPharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis Rheum200756310211028 Erratum in: Arthritis Rheum. 2007;56(4):137017328081
   PubMed Web of Science ®Google Scholar
• SundyJSBeckerMABarafHSfor Pegloticase Phase 2 Study InvestigatorsReduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized studyArthritis Rheum20085892882289118759308
   PubMed Web of Science ®Google Scholar
• YueCSHuangWAltonMPopulation pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure goutJ Clin Pharmacol200848670871818420531
   PubMed Web of Science ®Google Scholar
• AndersonASinghJAPegloticase for chronic goutCochrane Database Syst Rev20103CD00833520238366
   PubMedGoogle Scholar
• BarafHSMatsumotoAKMaroliANWaltripRWIIResolution of gouty tophi after twelve weeks of pegloticase treatmentArthritis Rheum200858113632363418975338
   PubMedGoogle Scholar
• SundyJSBarafHSBeckerMAEfficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): phase 3 results from GOUT1 and GOUT2 [abstract]Arthritis Rheum200858Suppl 9S635
   Google Scholar
• SundyJSBarafHSBeckerMAEfficacy and safety of intravenous pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2 [abstract]Ann Rheum Dis200968Suppl 3S318
   PubMedGoogle Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
   PubMed Web of Science ®Google Scholar
• WolfeFKleinhekselSMCatheyMAHawleyDJSpitzPWFriesJFThe clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritisJ Rheumatol19881510148014883204597
   PubMed Web of Science ®Google Scholar
• MaroliANWaltrip1RAltonMFirst application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract] Available from: http://acr.confex.com/acr/2009/webprogram/Paper16299.htmlAccessed 2010 Jul 7
   Google Scholar
• BarafHSBeckerMAEdwardsNLTophus response to pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials [abstract]Arthritis Rheum200858Suppl 9S22
   Google Scholar
• BarafHSBeckerMAEdwardsNLReduction of tophus size with pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2 [abstract]Ann Rheum Dis200968Suppl 3S84
   PubMedGoogle Scholar
• EdwardsNLBarafHSBeckerMAImprovement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3, randomized, double blind, placebo (PBO)-controlled trials [abstract]Arthritis Rheum200858Suppl 9S27
   Google Scholar
• StrandVEdwardsNLBarafHSImprovement in health-related quality of life (HRQOL) in patients with treatment failure gout (TFG) treated with pegloticase measured by SF-6D derived utility [abstract] Available from: http://acr.confex.com/acr/2009/webprogram/Paper14050.htmlAccessed 2010 Jul 7
   Google Scholar
• SundyJSBarafHSGutierrez-UrenaSRChronic use of pegloticase: safety and efficacy update [abstract]Arthritis Rheum200960Suppl 10S417
   Google Scholar
• BurnsCMWortmannRLGout therapeutics: new drugs for an old diseaseLancet2010416 [Epub ahead of print]
   Web of Science ®Google Scholar
• SchlesingerNNew agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyondCurr Rheumatol Rep201012213013420425022
   PubMedGoogle Scholar
• BeckerMATreadwellELBarafHSImmunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2 PGL phase 3 randomized, double blind, placebo-controlled trials [abstract]Arthritis Rheum200858Suppl 9S1945
   Google Scholar
• WrightDSundyJSRosario-JansenTRoutine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy [abstract]Arthritis Rheum200960Suppl 10S413
   Google Scholar
• BrowningLAKruseJAHemolysis and methemoglobinemia secondary to rasburicase administrationAnn Pharmacother200539111932193516204390
   PubMed Web of Science ®Google Scholar
• GóthLBiglerNWCatalase deficiency may complicate urate oxidase (rasburicase) therapyFree Radic Res200741995395517729111
   PubMed Web of Science ®Google Scholar